The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…one at a time

Immunologic Research
Jessica QuinnFred Modell

Abstract

Severe combined immunodeficiency (SCID) is a group of syndromes resulting from genetic defects causing severe deficiency in T cell and B cell function. These conditions are life-threatening and result in susceptibility to serious infections. SCID is often fatal in the first year of life if not detected and properly treated. SCID and related T cell lymphopenias can be detected in newborns by a simple screening test, the T cell receptor excision circle (TREC) assay, using the same dried blood spot samples already collected from newborns to screen for other genetic disorders. The TREC assay facilitates the earliest possible identification of cases of SCID before opportunistic infections, irreversible organ damage, or death, thus allowing for the possibility of curative treatment through hematopoietic stem cell transplant and gene therapy. Infants receiving hematopoietic stem cell transplant in the first few months of life, after being identified through screening, have a high probability of survival (95-100%), along with lower morbidity. The TREC assay has proven to have outstanding specificity and sensitivity to accurately identify almost all infants with SCID (the primary targets) as well as additional infants having other selec...Continue Reading

References

Feb 18, 1999·The New England Journal of Medicine·R H BuckleyF E Ward
Dec 10, 2009·JAMA : the Journal of the American Medical Association·John M RoutesMei W Baker
Oct 28, 2010·JAMA : the Journal of the American Medical Association·Bridget M Kuehn
Aug 4, 2011·Molecular Genetics and Metabolism·Kee ChanMichael Apkon
Jul 14, 2012·Blood·Amel HassanUNKNOWN Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation and European Society for Immunodefici
Jul 3, 2013·The Journal of Allergy and Clinical Immunology·Antonia KwanJennifer M Puck
Sep 27, 2013·Clinical Epidemiology·Brian T KellyJohn M Routes
Mar 29, 2014·Journal of Clinical Immunology·Stuart P AdamsH Bobby Gaspar
Jul 31, 2014·The New England Journal of Medicine·Sung-Yun PaiRichard J O'Reilly
Aug 21, 2014·JAMA : the Journal of the American Medical Association·Antonia KwanVincent R Bonagura
Dec 3, 2014·The Journal of Allergy and Clinical Immunology. in Practice·Catherine KubiakElena E Perez
Apr 22, 2015·Journal of Clinical Immunology·Jet van der SpekJoris M van Montfrans
Feb 6, 2019·Frontiers in Physiology·Ilya KorsunskiyDaniel Munblit
Jun 1, 2017·International Journal of Neonatal Screening·Morna Dorsey, Jennifer Puck
Oct 18, 2019·Frontiers in Pediatrics·Mirjam van der BurgSung-Yun Pai

❮ Previous
Next ❯

Citations

Nov 25, 2020·Pediatric Clinics of North America·Susan E Pacheco, James M Stark
Nov 6, 2020·Current Opinion in Pediatrics·Juan C Aldave-BecerraClaudia A Rentería-Valdiviezo
May 15, 2021·Neuromuscular Disorders : NMD·Tamara DangouloffUNKNOWN SMA NBS World Study Group
Jul 9, 2021·Journal of Multidisciplinary Healthcare·Sharon A McGrath-MorrowHoward M Lederman

❮ Previous
Next ❯

Methods Mentioned

BETA
flow-cytometry
flow cytometry

Related Concepts

Related Feeds

B cell Activation

B cell activation is initiated by the ligation of the B cell receptor with antigen and ultimately results in the production of protective antibodies against potentially pathogenic invaders. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.